Candriam S.C.A. Blueprint Medicines Corp Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	BUY	$85.18 - $108.78 $1.02 Million - $1.31 Million	12,001 Added 29.95%	52,066 $5.61 Million
Q1 2024 May 03, 2024	SELL	$73.17 - $99.79 $743,114 - $1.01 Million	-10,156 Reduced 20.22%	40,065 $3.8 Million
Q4 2023 Feb 14, 2024	SELL	$43.96 - $92.84 $3.74 Million - $7.89 Million	-85,001 Reduced 62.86%	50,221 $4.63 Million
Q3 2023 Nov 13, 2023	SELL	$46.9 - $66.0 $750,400 - $1.06 Million	-16,000 Reduced 10.58%	135,222 $6.79 Million
Q2 2023 Aug 08, 2023	SELL	$42.2 - $66.37 $12.8 Million - $20.1 Million	-302,790 Reduced 66.69%	151,222 $9.56 Million
Q1 2023 May 12, 2023	BUY	$37.97 - $50.0 $7.43 Million - $9.79 Million	195,701 Added 75.76%	454,012 $20.4 Million
Q3 2022 Nov 10, 2022	BUY	$49.93 - $77.7 $56,870 - $88,500	1,139 Added 0.44%	258,311 $17 Million
Q2 2022 Aug 03, 2022	BUY	$45.23 - $70.15 $3.06 Million - $4.75 Million	67,731 Added 35.75%	257,172 $13 Million
Q1 2022 May 13, 2022	SELL	$54.1 - $110.08 $8.81 Million - $17.9 Million	-162,802 Reduced 46.22%	189,441 $12.1 Million
Q4 2021 Feb 10, 2022	BUY	$94.25 - $115.99 $3.7 Million - $4.56 Million	39,293 Added 12.56%	352,243 $37.7 Million
Q2 2021 Jul 20, 2021	SELL	$82.78 - $101.0 $3.22 Million - $3.93 Million	-38,931 Reduced 11.06%	312,950 $27.5 Million
Q1 2021 Apr 29, 2021	SELL	$90.71 - $108.28 $90 - $108	-1 Reduced -0.0%	351,881 $37.9 Million
Q4 2020 Jan 22, 2021	SELL	$92.08 - $124.48 $16.8 Million - $22.7 Million	-182,133 Reduced 34.11%	351,882 $39.5 Million
Q3 2020 Oct 19, 2020	SELL	$66.45 - $92.7 $22.9 Million - $31.9 Million	-344,629 Reduced 39.22%	534,015 $49.5 Million
Q2 2020 Jul 23, 2020	BUY	$57.09 - $79.27 $43.8 Million - $60.8 Million	767,413 Added 689.93%	878,644 $68.5 Million
Q1 2020 May 26, 2020	BUY	$48.11 - $82.22 $1,924 - $3,288	40 Added 0.04%	111,231 $8.71 Million
Q4 2019 Jan 21, 2020	BUY	$66.73 - $82.59 $7.42 Million - $9.18 Million	111,191 New	111,191 $9,000
Q4 2018 Feb 14, 2019	SELL	$45.57 - $74.26 $2.05 Million - $3.34 Million	-45,000 Closed	0 $0
Q3 2018 Nov 07, 2018	BUY	$58.91 - $78.32 $58,910 - $78,320	1,000 Added 2.27%	45,000 $3.51 Million
Q4 2017 Feb 07, 2018	BUY	$62.91 - $88.32 $2.77 Million - $3.89 Million	44,000	44,000 $3.32 Million

Others Institutions Holding BPMC

# of Institutions

351

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

Vanguard Group Inc Valley Forge, PA

6.68M
Shares

$605 Million
0.01% of portfolio
Black Rock Inc. New York, NY

6.65M
Shares

$601 Million
0.02% of portfolio
Price T Rowe Associates Inc Baltimore, MD

5.39M
Shares

$487 Million
0.06% of portfolio
Wellington Management Group LLP Boston, MA

3.96M
Shares

$359 Million
0.07% of portfolio
State Street Corp Boston, MA

2.77M
Shares

$250 Million
0.01% of portfolio

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account